Lorlatinib, the world's first third-generation ALK (anaplastic lymphoma kinase)/ROS1 tyrosine kinase inhibitor (TKI), was developed by Pfizer for ···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 201
Lorlatinib was approved for marketing in China by the National Medical Products Administration (NMPA) in April 2022 and has been included in the Natio···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 224
Lorlatinib is a novel third-generation small-molecule ALK/ROS1 dual-target inhibitor developed by Pfizer Inc.Side effects requiring immediate medical ···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 204
Lorlatinib was first approved for marketing in Japan in September 2018, followed by approval from the U.S. Food and Drug Administration (FDA) in Novem···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 191
On October 12, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved cannefenib in combination with bimetinib for the t···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 202
In June 2018, the U.S. Food and Drug Administration (FDA) approved binimetinib for marketing as a treatment for unresectable metastatic melanoma or me···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 202
Lusutrombopag is a man-made form of a protein that increases production of platelets (blood-clotting cells) in your body. Lusutrombopag can lower the ···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 233
Take the missed dose on the same day you remember it. Take your next dose at the regular time and stay on your once-daily schedule. Do not use 2 doses···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 240
Follow your doctor's instructions about any restrictions on food, beverages, or activity.【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 237
Other drugs may affect lusutrombopag, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 229
Latest Prices of Different Versions of LusutrombopagLusutrombopag is a novel oral small‑molecule thrombopoietin receptor agonist (TPO‑RA). It promotes···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 221
Latest Price of Lusutrombopag in 2026Lusutrombopag is an oral small‑molecule thrombopoietin‑mimetic drug indicated for the treatment of thrombocytopen···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 212
Dosage and AdministrationDosing RegimenThe starting dose is 3 mg once daily, administered on an empty stomach (1 hour before or 2 hours after a meal).···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 199
Lusutrombopag is an oral thrombopoietin receptor agonist (TPO-RA). It is mainly used to treat increased bleeding risk due to thrombocytopenia in adult···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 198
Clinical Need for Thrombocytopenia TreatmentThrombocytopenia can result from many factors and is a common complication of chronic liver disease. Patie···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 186
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos